FBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Market Wrap: IMF Cuts FY15, FY16 Global Growth Outlook; Pepsi 'Pops' on Q3 Results; Yum! Q3 China Comps MissOctober 6, 2015 5:26 PM After-Hours Stock Movers 10/06: (ADXS) (YUM) (ADBE) Lower (more...)October 6, 2015 5:03 PM FDA Places Clinical Hold on Advaxis' (ADXS) Axalimogene Filolisbac IND ApplicationOctober 6, 2015 4:02 PM Advaxis Reports Clinical Hold of Investigational Agent Axalimogene FilolisbacOctober 6, 2015 4:01 PM Advaxis (ADXS) halted with news pendingOctober 6, 2015 4:01 PM